Sonic may well have the contract (I thougth all pathology providers could do it), but you suspect in a few years that the number of FIT tests will be approximating zero if the RHY test is superior and easier. Its not a threat, as FIT is the one threatened. You do realise that the $12b or total market opportunity refers to the value of tests. Only some of that will flow through to RHY. That amount is the biggest drivers of the various DCFs floating around
RHY Price at posting:
$1.84 Sentiment: Hold Disclosure: Held
